New EU Speedy Review Hopefuls: Novimmune, AveXis, bluebird bio, and Loxo Oncology

 
• By Maureen Kenny

It is not easy for companies to convince the European Medicines Agency that their marketing applications merit accelerated assessment. Four new hopefuls are about to find out whether they have been successful.

Business time concept as a group of running businessmen and businesswomen using a giant clock to cross over a cliff as a bridge as a metaphor for schedule and appointment speed as a 3D illustration.
The EMA is deciding whether to fast track four products

More from Review Pathways

More from Pathways & Standards